1p/19q共缺失少突胶质细胞瘤 upfront 化疗后15年生存率达80%,与肿瘤分级无关
该长期回顾性研究纳入70例1p/19q共缺失少突胶质细胞瘤患者(48例WHO II级,22例III级),均接受upfront化疗而不行常规放疗。中位随访13年,5年、10年、15年无进展生存率分别为85.7%、54.8%、31.5%,总生存率分别为96.8%、88.7%、80.0%,中位总生存未达到。
要点
- 1p/19q共缺失少突胶质细胞瘤upfront化疗后15年总生存率达80.0%。
- 中位无进展生存146个月,中位总生存未达到。
- 肿瘤WHO分级、手术切除程度和年龄均不影响无进展生存或总生存。
核心结论
- 20年单中心经验表明,1p/19q共缺失少突胶质细胞瘤患者仅接受upfront化疗即可成功治疗,且不损害总生存。
研究设计与样本
- 长期回顾性研究,纳入70例非选择性的1p/19q共缺失少突胶质细胞瘤连续患者(48例WHO II级,22例WHO III级),均统一接受upfront化疗而不行常规放疗。
主要发现
- 中位随访13年,5年、10年、15年无进展生存率分别为85.7%、54.8%、31.5%,中位无进展生存146个月。
- 5年、10年、15年总生存率分别为96.8%、88.7%、80.0%,中位总生存未达到。
- 多数病例肿瘤复发仍为局部,可通过挽救性手术和/或化疗控制。
- 基于WHO分类的肿瘤分级、手术切除程度和年龄均不影响无进展生存或总生存。
- 多数患者能够恢复至病前社会生活。
临床怎么用
- 作者认为,1p/19q共缺失少突胶质细胞瘤患者仅接受upfront化疗即可成功治疗,且不损害总生存。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Chromosomes 1p/19q co-deletion is a robust molecular marker for the diagnosis of oligodendroglial tumors, and has been included in the 2016 WHO modified classification. Although treatment for oligodendroglioma is controversial, upfront chemotherapy is regarded as one of the treatment option for low-grade tumor. We have treated all the 1p/19q co-deleted oligodendrogliomas, both grades II and III, with upfront chemotherapy without conventional radiotherapy for 20 years. The clinical experience from this trial may be suggestive for understanding of the biological features of oligodendroglioma with 1p/19q co-deletion toward precision medicine. METHODS: This is a long-term retrospective data of the non-selected patients with 1p/19q co-deleted oligodendrogliomas uniformly treated with up-front chemotherapy. Seventy consecutive patients (48 with grade II and 22 with grade III tumors) were included. RESULTS: The median follow-up period was 13 years. The 5-, 10-, and 15-year progression-free survival (PFS) rates were 85.7%, 54.8%, and 31.5%, respectively, and the median PFS was 146 months. In most cases, tumor recurrence was remained local and could be controlled by salvage surgery and/or chemotherapy. The 5-, 10-, and 15-year overall survival (OS) rates were 96.8%, 88.7%, and 80.0%, respectively, and the median OS was not reached. These survival data compared favorably with previous large clinical studies employing radiotherapy. Tumor grades based on World Health Organization classification, extent of surgery, and age affected neither PFS nor OS. Most patients were able to return to their premorbid social life. CONCLUSIONS: The long-term results drawn from 20-years of single institution experience show that the patients with 1p/19q co-deleted oligodendrogliomas can be successfully treated with up-front chemotherapy alone without compromising OS.
引用
- Iwadate Y, Matsutani T, Hara A, et al. Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade. J Neurooncol. 2018. PMID: 30565028. doi:10.1007/s11060-018-03027-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。